DEA Opens Cannabis Rescheduling Hearing as Schedule III Move Advances

DEA Hearing Enters Day One with Medical Evidence

The administrative law judge hearing opened with researchers presenting evidence on cannabis's accepted medical use, the central legal question under the Controlled Substances Act. The hearing follows the DEA's August 2024 notice of proposed rulemaking to reschedule cannabis based on a Health and Human Services Department recommendation.

Witnesses addressed abuse potential, pharmacology, scientific evidence of medical use, and the drug's history and current pattern of use.

Who Testified and What They Said

Medical researchers from academic institutions presented peer-reviewed studies on cannabis efficacy for chronic pain, nausea, and muscle spasticity. The DEA called its own expert witnesses to address abuse liability and diversion risk under a Schedule III classification.

Industry groups including the National Cannabis Industry Association and multi-state operators submitted written testimony and appeared for cross-examination. State regulators from California, Colorado, and Michigan testified on operational compliance frameworks that could adapt to Schedule III requirements.

The 280E Tax Question Looms Large

Rescheduling to Schedule III would eliminate the IRC 280E tax burden that currently prevents cannabis businesses from deducting ordinary business expenses. Industry witnesses said 280E repeal would reduce effective tax rates from 70-80% to standard corporate rates of 21-35%, freeing capital for compliance infrastructure and patient access programs.

The financial stakes? Multi-state operators currently pay $400 million to $600 million annually in excess federal taxes attributable solely to 280E. Rescheduling would redirect that capital to operations, potentially lowering consumer prices 10-15% within 12 months.

Opposition Groups Raise Diversion and Youth Access Concerns

Anti-legalization organizations including Smart Approaches to Marijuana said Schedule III classification would increase youth access and normalize recreational use. Their witnesses cited potency data showing THC concentrations in commercial products now exceed 20-30%, far above levels studied in clinical trials supporting the HHS recommendation.

DEA's own witnesses acknowledged that Schedule III drugs face fewer manufacturing and distribution controls than Schedule I or II substances. How does the agency plan to prevent diversion of pharmaceutical-grade cannabis into recreational markets in states without adult-use programs? That question needs an answer.

Timeline and Next Steps for Final Rule

The hearing is scheduled to run five days, with closing briefs due 30 days after the transcript is finalized. The ALJ will issue a recommended decision to the DEA Administrator, who retains final authority to accept, reject, or modify the recommendation.

Legal observers expect the ALJ's recommendation by October 2026. A final DEA rule could arrive by early 2027. The Administrative Procedure Act requires the agency to respond to all substantive public comments—more than 43,000 were submitted during the comment period—before issuing a final rule.

State-Legal Markets Watch for Federal Alignment

State cannabis regulators are preparing compliance frameworks that would align state licensing with federal Schedule III requirements. Key variables include:

• Whether DEA will require state-licensed operators to register as Schedule III handlers
• How state testing and tracking systems will interface with federal pharmaceutical-grade standards
• Whether interstate commerce in cannabis will be permitted under Schedule III
• How the FDA will regulate cannabis products if rescheduling is finalized

California's Department of Cannabis Control and New York's Office of Cannabis Management both said they're monitoring the hearing closely and will issue guidance to licensees once the final rule is published.

What Operators Should Watch

The hearing record will form the basis for any legal challenges to the final rule, making the quality of evidence presented this week critical. If the DEA finalizes rescheduling, operators should expect a 6-12 month implementation window before 280E relief takes effect, based on IRS guidance timelines for prior tax code changes.

Cannabis businesses should begin scenario planning now for Schedule III compliance costs, including potential DEA registration fees, enhanced security requirements, and pharmaceutical-grade quality control systems. Compliance costs will vary significantly based on the final rule's specifics, but early preparation will minimize disruption when the rule takes effect.

We'll be watching for the ALJ's recommended decision in October and tracking state regulatory guidance as it emerges. For full background, see the CannIntel topic hub on DEA Cannabis Rescheduling.